Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CDT Stock Forecast 2025-2026
$1.79
Current Price
$2.42M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CDT Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CDT Price Momentum
-11.8%
1 Week Change
-27.2%
1 Month Change
-99.8%
1 Year Change
-99.8%
Year-to-Date Change
-99.9%
From 52W High of $2,196.00
+20.9%
From 52W Low of $1.48
📊 TOP ANALYST CALLS
Did CDT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Conduit Pharma is one of their latest high-conviction picks.
Latest CDT Stock Price Targets & Analyst Predictions
CDT has shown a year-to-date change of -99.8% and a 1-year change of -99.8%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CDT. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CDT Analyst Ratings
0
Buy
0
Hold
0
Sell
CDT Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.79
Latest CDT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CDT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Conduit Pharmaceuticals Inc. (CDT) Competitors
The following stocks are similar to Conduit Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CDT
Conduit Pharmaceuticals
mkt cap
2.75M
Conduit Pharmaceuticals Inc. (CDT) Financial Data
Conduit Pharmaceuticals Inc. has a market capitalization of $2.42M with a P/E ratio of 421.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +262.1%.
Valuation Metrics
Market Cap
$2.42M
Enterprise Value
$1.00M
P/E Ratio
421.3x
PEG Ratio
-4.8x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+131.6%
Current Ratio
1.7x
Debt/Equity
43.8x
ROE
+262.1%
ROA
-207.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Conduit Pharmaceuticals Inc. (CDT) Business Model
About Conduit Pharmaceuticals Inc.
What They Do
Develops innovative therapeutic treatments for chronic diseases.
Business Model
Conduit Pharmaceuticals generates revenue through the advancement of clinical phase drug candidates aimed at treating chronic diseases with significant unmet needs. Their business model relies on a robust research and development pipeline that emphasizes novel therapies in high-demand areas such as autoimmune disorders and oncology.
Additional Information
The company collaborates with research institutions and healthcare entities to enhance its drug development capabilities. By focusing on scientific excellence and patient-centric innovation, Conduit Pharmaceuticals aims to deliver breakthrough therapies that can significantly impact global health challenges and improve patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
7
CEO
Dr. David Joszef Tapolczay
Country
United States
IPO Year
2023
Website
www.conduitpharma.comConduit Pharmaceuticals Inc. (CDT) Latest News & Analysis
Latest News
CDT Equity Increases Bitcoin Holding
1 month ago
Quick Summary
CDT Equity Inc. acquired 9.2565 Bitcoin for $1,005,000, averaging $108,301.75 per BTC. The transaction was announced on October 17, 2025.
Why It Matters
CDT's acquisition of Bitcoin signals confidence in cryptocurrency, potentially impacting its stock value and attracting investor interest in digital assets.
Source: GlobeNewsWire
Market Sentiment:
Neutral
CDT Equity Inc. Announces Reverse Stock Split
1 month ago
Quick Summary
CDT Equity Inc. (Nasdaq: CDT) has announced a 1-for-8 reverse stock split of its common stock, approved by the board of directors.
Why It Matters
A 1-for-8 reverse stock split may indicate efforts to boost share price and attract institutional investors, impacting liquidity and overall market perception of CDT.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
No significant financial information is provided in the excerpt. Further details are needed for a relevant investor summary.
Why It Matters
The mention of Naples and Cambridge may indicate significant developments or partnerships that could affect local economies or industries, influencing investment opportunities in those regions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CDT Equity Inc. (Nasdaq: CDT) has identified a new biological target for its lead program AZD1656, following positive pre-clinical study results.
Why It Matters
The identification of a new biological target and positive pre-clinical data for AZD1656 may enhance CDT's drug pipeline, potentially leading to increased market value and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Conduit to Change Name to CDT Equity Inc.
4 months ago
Quick Summary
Conduit Pharmaceuticals Inc. plans to change its name to CDT Equity Inc. to reflect its new strategy focused on advancing therapeutic assets through innovation and partnerships.
Why It Matters
The name change to CDT Equity Inc. signals a strategic shift toward a data-driven biotech focus, which may boost investor confidence in growth potential and innovative partnerships.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Conduit Pharmaceuticals filed four new patent applications for AZD1656 and AZD5658, including its first for AZD5658, following AI-led analysis with Sarborg Limited.
Why It Matters
Patent filings indicate potential for innovative drug development and market exclusivity, which can enhance company valuation and attract investor interest in Conduit Pharmaceuticals.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CDT Stock
What is Conduit Pharmaceuticals Inc.'s (CDT) stock forecast for 2026?
Analyst forecasts for Conduit Pharmaceuticals Inc. (CDT) are not currently available. The stock is trading at $1.79.
Is CDT stock a good investment in 2026?
Analyst ratings for CDT are not currently available. The stock is currently trading at $1.79. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CDT stock?
Price predictions from Wall Street analysts for CDT are not currently available. The stock is trading at $1.79.
What is Conduit Pharmaceuticals Inc.'s business model?
Conduit Pharmaceuticals generates revenue through the advancement of clinical phase drug candidates aimed at treating chronic diseases with significant unmet needs. Their business model relies on a robust research and development pipeline that emphasizes novel therapies in high-demand areas such as autoimmune disorders and oncology.
What is the highest forecasted price for CDT Conduit Pharmaceuticals Inc.?
Price targets from Wall Street analysts for CDT are not currently available. The stock is trading at $1.79.
What is the lowest forecasted price for CDT Conduit Pharmaceuticals Inc.?
Price targets from Wall Street analysts for CDT are not currently available. The stock is trading at $1.79.
What is the overall CDT consensus from analysts for Conduit Pharmaceuticals Inc.?
Analyst ratings for CDT are not currently available. The stock is trading at $1.79.
How accurate are CDT stock price projections?
Stock price projections, including those for Conduit Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 6, 2025 6:47 PM UTC